ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
MWN-AI** Summary
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) has announced three significant poster presentations that will take place at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 23-27, 2026, in Madrid, Spain. The presentations will focus on their clinical candidates enozertinib and rinzimetostat, showcasing the company's commitment to addressing therapeutic resistance in oncology.
The first presentation will feature enozertinib (ORIC-114), a selective EGFR inhibitor designed for treating treatment-naive metastatic non-small cell lung cancer (NSCLC) with atypical mutations. This Phase 1b trial aims to highlight the drug's potential in improving outcomes for patients with this challenging form of cancer. This session is scheduled for October 26, 2026.
The second presentation will cover rinzimetostat, an allosteric PRC2 inhibitor, in the context of the ongoing Himalayas-1 Phase 3 study. This trial is focused on patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with abiraterone acetate. The session is set for October 23, 2026, and will emphasize the study's global design and objectives.
Lastly, ORIC will present data supporting rinzimetostat's ability to enhance androgen receptor (AR) signaling and restrict lineage plasticity in preclinical models of mCRPC. This presentation will provide mechanistic insights based on patient samples, further establishing the compound's therapeutic potential.
Abstracts for all presentations will be accessible on the ESMO Congress website starting October 19, 2026. ORIC Pharmaceuticals continues to strive for innovation in cancer therapy, with a focus on overcoming resistance mechanisms and enhancing patient care. For more details, visit their official website or follow them on social media platforms.
MWN-AI** Analysis
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) recently announced three key poster presentations at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. This presents an important opportunity for investors to assess the company’s progress and potential, particularly regarding its two leading candidates, enozertinib and rinzimetostat.
Enozertinib targets EGFR atypical mutations in treatment-naive metastatic non-small cell lung cancer (NSCLC), a segment with a significant need for innovative therapies. The company’s focus on a brain-penetrant and selective EGFR inhibitor may position it favorably in a competitive market. Given the rise in NSCLC cases, successful outcomes from the ongoing Phase 1b trial could bolster investor confidence and lead to increased demand for the stock.
Similarly, the rinzimetostat presentations at ESMO aim to shed light on its Phase 3 Himalayas-1 trial in metastatic castration-resistant prostate cancer (mCRPC) and its potential benefits over abiraterone acetate. The focus on enhancing androgen receptor (AR) signaling while limiting lineage plasticity could attract interest, particularly as treatment options for mCRPC continue to evolve. Positive trial results could significantly elevate ORIC's valuation and pave the way for new partnerships or licensing deals.
Investors should closely monitor the outcomes presented at ESMO 2026, as these findings will impact market positioning. Furthermore, public access to abstract data on October 19, 2026, provides an early glimpse into the efficacy of these candidates, potentially influencing stock volatility leading up to the congress.
In summary, ORIC Pharmaceuticals presents a compelling investment opportunity predicated on promising clinical developments. Monitoring the upcoming presentations will provide critical insights into their future trajectory as they seek to overcome therapeutic resistance in oncology.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC
Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone
Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.
Poster presentation details:
| Title: | Enozertinib (ORIC-114), a Brain Penetrant, Highly Selective EGFR Inhibitor, in Treatment-Naive Metastatic NSCLC with EGFR Atypical Mutations |
| Presentation Number: | 2627P |
| Session Date & Time: | Monday, October 26, 2026; 12:00 – 12:45 p.m. CET |
| Session Title: | Metastatic NSCLC |
| Title: | Rinzimetostat, an Allosteric PRC2 Inhibitor Combined With Darolutamide: A Global Phase 3 Study in mCRPC Patients Previously Treated With Abiraterone Acetate (Himalayas-1) |
| Presentation Number: | 2303TiP |
| Session Date & Time: | Friday, October 23, 2026; 3:15 – 4:00 p.m. CEST |
| Session Title: | Metastatic Prostate Cancer |
| Title: | Rinzimetostat, a Next-Generation PRC2 Inhibitor, Enhances Luminal Fate and AR Signaling While Restricting Lineage Plasticity in Preclinical Models and Demonstrates Mechanistic Proof-of-Concept in Samples From Patients with mCRPC |
| Presentation Number: | 1128eP |
| Session Title: | Developmental Therapeutics |
Full abstracts will be available for public viewing via the ESMO Congress website on October 19, 2026.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ**
What are the key efficacy and safety outcomes reported for enozertinib in the ongoing Phase trial in treatment-naive patients with EGFR atypical NSCLC, as highlighted by Oric Pharmaceuticals Inc. ORIC in their recent poster presentation?
How does the Himalayas-1 Phase 3 study design, presented by Oric Pharmaceuticals Inc. ORIC, aim to evaluate the effectiveness of rinzimetostat combined with darolutamide in mCRPC patients previously treated with abiraterone?
Can you elaborate on the mechanisms by which rinzimetostat enhances AR signaling and restricts lineage plasticity in mCRPC, as supported by data from the presentation by Oric Pharmaceuticals Inc. ORIC?
What are the potential clinical implications of the findings presented by Oric Pharmaceuticals Inc. ORIC at the ESMO Congress 2026 regarding the role of enozertinib and rinzimetostat in their respective patient populations?
**MWN-AI FAQ is based on asking OpenAI questions about Oric Pharmaceuticals Inc. (NASDAQ: ORIC).
NASDAQ: ORIC
ORIC Trading
-3.15% G/L:
$10.47 Last:
436,885 Volume:
$10.755 Open:
ORIC Latest News
